Eupraxia Pharma reports positive data from RESOLVE phase 1b/2a trial of EP-104GI for treatment of eosinophilic esophagitis: Victoria, British Columbia Thursday, November 14, 2024, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback